About Us

We're here to transform the lives of people affected by neuromuscular disease.

Press Releases

Nationwide Thousands of Businesses Unite to Help Save Lives through MDA Shamrocks

Submitted by KReddy on Wed, 03/01/2017 - 09:27

The program now in its 35^th year has raised millions to support families with muscular dystrophy, ALS and related life-threatening diseases.
MDA Names Kristine Welker Interim CEO

Submitted by KReddy on Mon, 02/13/2017 - 15:37

CHICAGO, February 13, 2017— MDA today announced that Kristine Welker, a member of the Board of Directors, has been appointed Interim President and Chief Executive Officer, effective immediately, and is succeeding Steve Derks, MDA's President and Chief Executive Officer since December 2012, who is stepping down after helping lead MDA through this important time of transformation.
MDA Celebrates News of FDA Approval of Emflaza for Treatment of Duchenne Muscular Dystrophy

Submitted by KReddy on Thu, 02/09/2017 - 12:21

CHICAGO, February 9, 2017— The Muscular Dystrophy Association today welcomed news of the U.S. Food and Drug Administration’s decision to grant approval for deflazacort (brand name Emflaza), under development by Marathon Pharmaceuticals, to treat the most common childhood form of muscular dystrophy.
Southeast Division Circle K’s Reach Over $1 Million in Support for Families Fighting Muscle-Debilitating Diseases

Submitted by KReddy on Mon, 02/06/2017 - 11:18

The retailer’s eight-year partnership with MDA continues to thrive with the support of employees and customers.
MDA Awards Nearly $1 Million to Continue Funding Myotonic Dystrophy Clinical Research Network

Submitted by KReddy on Tue, 01/24/2017 - 10:30

Investment will support five medical centers that specialize in DM research and clinical care

CHICAGO, January 24, 2017 – The Muscular Dystrophy Association announces the award of a clinical research network grant totaling $918,000 over three years to spur advances in myotonic dystrophy (DM) research.
MDA Celebrates FDA Approval of Spinraza for Treatment of Spinal Muscular Atrophy

Submitted by amadsen on Fri, 12/23/2016 - 16:37

‘Antisense’ drug expected to change — and save — lives

CHICAGO, December 23, 2016— The Muscular Dystrophy Association today celebrated news of the U.S. Food and Drug Administration’s decision to grant approval for nusinersen (brand name Spinraza), the first disease-modifying drug to treat the most common genetic cause of death in infants.

« first
‹ previous
…
10
11
12
13
14
15
16
17
18
…
next ›
last »

Our Story

Our Team

Resources

Care Centers

Family Seminars

MDA Resource Hub

Summer Camp

Our Approach

For Researchers

For Clinicians

Participate

Donate

Partner

About Us

Press Releases

Nationwide Thousands of Businesses Unite to Help Save Lives through MDA Shamrocks

MDA Names Kristine Welker Interim CEO

MDA Celebrates News of FDA Approval of Emflaza for Treatment of Duchenne Muscular Dystrophy

Southeast Division Circle K’s Reach Over $1 Million in Support for Families Fighting Muscle-Debilitating Diseases

MDA Awards Nearly $1 Million to Continue Funding Myotonic Dystrophy Clinical Research Network

MDA Celebrates FDA Approval of Spinraza for Treatment of Spinal Muscular Atrophy

Find MDA
in your Community

Sign Up for MDA News & Updates

About Us

Press Releases

Nationwide Thousands of Businesses Unite to Help Save Lives through MDA Shamrocks

MDA Names Kristine Welker Interim CEO

MDA Celebrates News of FDA Approval of Emflaza for Treatment of Duchenne Muscular Dystrophy

Southeast Division Circle K’s Reach Over $1 Million in Support for Families Fighting Muscle-Debilitating Diseases

MDA Awards Nearly $1 Million to Continue Funding Myotonic Dystrophy Clinical Research Network

MDA Celebrates FDA Approval of Spinraza for Treatment of Spinal Muscular Atrophy

Find MDA in your Community

Find MDA
in your Community